Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avatrombopag for Thrombocytopenia After Allogeneic HCT
NCT04312789Phase 2Withdrawn
- Start
- Dec 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of avatrombopag in Thrombocytopenia. Primary endpoints: Incidence of adverse events of avatrombopag treatment and Failure rate of platelet recovery at Day 90. Planned start Dec 2022; status: withdrawn.
02
Drugs
avatrombopag
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT04312789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04312789.